Bioventus logo

BioventusNASDAQ: BVS

Profile

Sector:

Healthcare

Country:

United States

IPO:

11 February 2021

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$928.61 M
-6%vs. 3y high
73%vs. sector
-vs. 3y high
-vs. sector
-5%vs. 3y high
86%vs. sector
-30%vs. 3y high
34%vs. sector

Price

regular market | 2 min ago
$14.27+$0.69(+5.08%)

Dividend

No data over the past 3 years
$151.22 M$133.23 M
$151.22 M-$23.99 M

Analysts recommendations

Institutional Ownership

BVS Latest News

Are Medical Stocks Lagging Bioventus (BVS) This Year?
zacks.com04 November 2024 Sentiment: -

Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?
zacks.com29 October 2024 Sentiment: POSITIVE

Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
globenewswire.com29 October 2024 Sentiment: POSITIVE

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
zacks.com19 September 2024 Sentiment: POSITIVE

BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.

Bull Of The Day: Bioventus (BVS)
zacks.com29 August 2024 Sentiment: POSITIVE

This stock has seen 3 consecutive beats of the Zacks Consensus Estimate and also posted solid margin expansion.

Bioventus Inc. (BVS) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: NEUTRAL

Bioventus Inc. (NASDAQ:BVS ) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Bioventus Reports Second Quarter Financial Results
globenewswire.com06 August 2024 Sentiment: POSITIVE

DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 29, 2024.

Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
globenewswire.com30 July 2024 Sentiment: POSITIVE

DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Here's Why You Should Consider Buying Bioventus (BVS) Stock
zacks.com05 June 2024 Sentiment: POSITIVE

Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.

Bioventus: Bullish On Path To Profitability
Seeking Alpha24 January 2024 Sentiment: POSITIVE

Shares of BVS are up more than 100% over the past year amid an ongoing financial turnaround. The company is benefiting from strong demand for its portfolio of minimally invasive medical treatment including therapeutic injections for osteoarthritis. Shares are attractively priced ahead of the Q4 earnings report where we expect management to deliver positive 2024 guidance.

  • 1(current)

What type of business is Bioventus?

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

What sector is Bioventus in?

Bioventus is in the Healthcare sector

What industry is Bioventus in?

Bioventus is in the Medical Devices industry

What country is Bioventus from?

Bioventus is headquartered in United States

When did Bioventus go public?

Bioventus initial public offering (IPO) was on 11 February 2021

What is Bioventus website?

https://www.bioventus.com

Is Bioventus in the S&P 500?

No, Bioventus is not included in the S&P 500 index

Is Bioventus in the NASDAQ 100?

No, Bioventus is not included in the NASDAQ 100 index

Is Bioventus in the Dow Jones?

No, Bioventus is not included in the Dow Jones index

When was Bioventus the previous earnings report?

No data

When does Bioventus earnings report?

The next expected earnings date for Bioventus is 07 November 2024